When Renal Replacement Therapy Begins: The Signs Nephrologists Use to Time the Start

The folder on the clinic desk has a graph in it. A line of small dots, one for each blood test over three years, sloping gently downhill. The man across the desk has stopped looking at the dots. He is looking at the empty space to the right of them, and he asks the question that brought him here: how do you decide when to start renal replacement therapy, and how will I know it is time?

His daughter, sitting beside him, has a different version of the same worry. She has read that dialysis starts at a certain number. She wants to know what the number is, and whether waiting is risky.

Both questions are fair. The honest answer is more interesting than a threshold, and more reassuring than most people expect. Kidney specialists time this decision by watching a person, not a value, and the evidence behind that approach is unusually strong.

What renal replacement therapy actually is, in plain language

Renal replacement therapy is the umbrella term for any treatment that takes over the filtering work of failed kidneys. In practice that means three things: hemodialysis, peritoneal dialysis, or a kidney transplant. Healthy kidneys clear waste products, balance salts such as potassium and sodium, remove excess water, and keep the blood from becoming too acidic. When they fail, something has to do those jobs.

Hemodialysis pumps blood out of the body through a filter and returns it cleaned. According to the NHS, most people on center-based hemodialysis attend about three sessions a week, each lasting around four hours. Peritoneal dialysis uses the lining of the abdomen as the filter; a sterile fluid is run into the belly through a soft tube, waste crosses into it, and the fluid is drained and replaced. A transplant replaces the filter altogether with a donated kidney, and for suitable candidates it can be planned before dialysis ever begins.

In intensive care, the same principle appears in a slower form called continuous renal replacement therapy, or CRRT. Instead of a four-hour session, blood is filtered gently around the clock, which suits people whose blood pressure is too fragile for rapid fluid shifts.

What none of these treatments do is repair the kidneys. Dialysis is a substitute, not a fix, and it replaces only part of what a kidney does. It does not, for example, produce the hormone that tells bone marrow to make red blood cells, so people on dialysis often need that managed separately. Understanding this shapes the timing debate: because dialysis carries its own burdens, starting it is a trade, and the goal is to make the trade when it clearly pays.

When to start renal replacement therapy: why there is no single number

People searching for when to start renal replacement therapy usually want a threshold. Kidney teams rarely use one, and for a good reason: the number most often quoted, the estimated glomerular filtration rate or eGFR, is an estimate of how much blood the kidneys filter each minute, derived from a creatinine level plus age and sex. It is a useful trend line. It is a poor trigger.

Consider two people with the same eGFR of 9. One is eating well, has stable potassium, no swelling, and feels tired but functional. The other has lost appetite, wakes breathless at night, and has a potassium level drifting toward the danger zone. The first person can usually wait and be watched. The second is running out of time. The lab value cannot tell them apart; the clinician can.

The decision therefore rests on a cluster of questions that nephrologists ask at every visit. Is waste building up to the point of symptoms? Is fluid accumulating faster than diuretic medicines can remove it? Are potassium and acid levels holding within safe limits, or slipping despite diet changes? How steep is the slope of decline, and is a transplant realistically close? What does the person want, and what will fit the life they are trying to live?

The NIH’s kidney institute describes kidney failure as a state where the kidneys keep only a small fraction of normal function and describes the treatment choice as one made together with the care team, weighing lifestyle, health and preference. That framing is the truth of it. Timing is a judgment, informed by numbers, owned by the person and their treating team.

At what eGFR level do you start dialysis?

The number most people have heard is 15. An eGFR below 15 defines kidney failure, sometimes called stage 5 chronic kidney disease, according to the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. That definition explains why the figure circulates, and also why it misleads. Reaching stage 5 means the kidneys have very little reserve left. It does not mean dialysis begins that week.

In practice many people live for months, sometimes longer, below an eGFR of 15 before treatment starts, provided they feel reasonably well and their blood tests stay safe. The IDEAL trial, published in the New England Journal of Medicine and indexed on PubMed, tested this directly. Researchers randomized 828 adults with advanced kidney disease to a planned early start, at an eGFR of 10 to 14, or a planned late start, at 5 to 7. Survival over the follow-up period was no different between the groups. People in the late group waited a median of about six months longer before dialysis began.

One detail from that trial deserves attention. About three quarters of those assigned to the late group actually started before their eGFR fell to 7, because symptoms or fluid problems prompted their doctors to act. The number set the plan; the person set the timing.

What this means for the question in the heading: there is no eGFR at which dialysis must begin. Values under 15 put a person in the window where preparation should be well under way and the conversation should be active. Values under 10 sharpen the watch. The trigger itself is usually clinical, not numerical.

The signs nephrologists weigh when deciding it's time to start dialysis

Ask a kidney specialist what tips the balance and you will hear a fairly consistent list, not of symptoms for patients to score at home, but of clinical problems the team tries to control by other means first and turns to dialysis when those means stop working.

The first is uremia, the buildup of waste products in the blood to a level that causes illness. Its effects are often gradual: appetite fades, food tastes metallic, nausea appears in the mornings, sleep becomes broken, concentration slips, and weight drifts down as muscle is lost. The NHS lists these among the features of advanced kidney disease. Once uremia begins to affect nutrition or thinking, waiting offers little.

The second is fluid overload that no longer responds to diuretics, the medicines that increase urine output. Swollen legs are common and manageable. Fluid collecting in the lungs, with breathlessness on lying flat, is a different matter and can become an emergency.

The third is blood chemistry that cannot be held safe by diet and medication. High potassium, called hyperkalemia, threatens heart rhythm. Metabolic acidosis, an excess of acid the kidneys can no longer excrete, weakens bone and muscle and, at severe levels, disturbs breathing and heart function.

The fourth is less dramatic but often decisive: a downward trend that is steepening, or a person whose overall condition is declining faster than the numbers alone would predict.

None of these is a home test. A person who notices persistent nausea, breathlessness or unusual weakness should report it promptly so the team can measure what is happening. The assessment, and the decision, belong to the clinicians who know the whole picture.

What the current AKI dialysis guidelines say about timing

Acute kidney injury, or AKI, is a sudden drop in kidney function over hours or days, usually in someone who is already ill from another cause such as sepsis, major surgery or severe dehydration. The NHS describes it as common in hospitalized patients and often reversible when the underlying cause is treated. Because it is sudden, the timing question in AKI is sharper than in chronic disease and has been studied more intensively in recent years.

International guidance from the KDIGO group, which many national bodies including NICE draw upon, stages AKI from 1 to 3 according to how far creatinine rises and how much urine output falls. The same guidance is deliberately cautious about dialysis timing. It recommends starting emergently when life-threatening changes in fluid, electrolytes or acid balance exist, and otherwise considering the broader clinical context, the trend of tests, and whether other treatments can correct the problem, rather than relying on a single creatinine or urea value.

That caution used to feel like a gap in the evidence. It now looks like wisdom, because the large trials that followed confirmed it. The most influential, STARRT-AKI, is discussed in the next section. Its result pushed practice away from pre-emptive starts and toward a strategy sometimes called watchful waiting: treat the cause, support the circulation, monitor closely, and begin renal replacement therapy when a specific, defined problem demands it.

In everyday hospital terms the guidance amounts to this. A patient in intensive care with severe AKI is not automatically connected to a machine. The team asks each day whether there is a reason that outweighs the risks of the treatment, and many patients recover without ever needing it.

Early vs late dialysis initiation: what the big trials found

For decades, intuition favored starting early. Toxins are bad; remove them sooner. The trouble with intuition is that dialysis is not free of harm. It requires a large catheter in a central vein, exposes blood to a circuit, can drop blood pressure, and may delay the kidneys’ own recovery by pulling off fluid and lowering perfusion. Randomized trials were needed to settle the trade.

The STARRT-AKI trial, published in the New England Journal of Medicine and indexed on PubMed, enrolled 3,019 critically ill adults with severe AKI across many countries. Half were assigned to an accelerated strategy, starting renal replacement therapy within hours of meeting criteria. The other half followed a standard strategy, starting only if a conventional indication developed, such as persistent severe AKI, high potassium, severe acidosis or fluid overload resistant to treatment.

Death at 90 days was essentially identical: 43.9 percent with the accelerated approach and 43.7 percent with standard care. Two secondary findings mattered more. Among survivors, more people in the accelerated group remained dependent on dialysis at 90 days, 10.4 percent versus 6.0 percent. And 38 percent of patients in the standard group never needed renal replacement therapy at all, because their kidneys recovered while the team waited.

The message for chronic kidney disease came from the IDEAL trial described earlier: planned early starts brought no survival benefit over symptom-guided later starts.

Taken together, the evidence supports a clear opinion. Starting dialysis to chase a number, in the absence of a clinical problem, exposes people to procedures they may not need. Starting when a defined indication appears, with preparation already done, gives up nothing in survival and spares a meaningful share of people a treatment they would otherwise have received unnecessarily.

Who is usually told to start renal replacement therapy, and who is asked to wait

Because timing is clinical, it helps to describe the two groups in the real terms teams use.

People usually advised to start soon share a pattern: evidence that the kidneys are failing to keep the body safe despite everything else being tried. That includes potassium that stays high after dietary limits and medicines that lower it, acid levels that cannot be corrected, fluid that keeps returning to the lungs, and symptoms of uremia that are eroding nutrition, sleep or thinking. In hospital, it also includes certain poisonings and drug overdoses where dialysis can remove the substance, though those situations sit outside the scope of this article.

People usually asked to wait, with close monitoring, are those whose numbers are low but whose bodies are coping. Their potassium is controlled, they are not overloaded with fluid, they are eating, and their eGFR is falling slowly or has plateaued. For them, the IDEAL trial’s findings apply directly: waiting under supervision does not shorten life, and every month without dialysis is a month of unrestricted schedule, fewer procedures and lower infection risk from access devices.

A third group is often overlooked: people who are candidates for a transplant from a living donor. For them the aim may be a pre-emptive transplant, arranged before dialysis is ever needed. The NIH kidney institute describes this option, and it changes the timing conversation entirely, because the goal becomes bridging safely to surgery rather than choosing a dialysis start date.

Finally, some people, particularly those who are very frail or living with several other serious illnesses, may be offered conservative management instead. That path is covered later. Whichever group a person falls into, the classification is provisional, reviewed at every visit, and made by the treating team with the person at the center.

Urgent start or planned start? A side-by-side look

Nephrologists talk about two kinds of beginnings, and the difference matters more than most people realize. A planned start follows months of preparation and usually begins in an outpatient unit. An urgent start happens in hospital because a problem has become dangerous. The table below sets them side by side, drawing on NHS and Mayo Clinic descriptions of how dialysis is delivered.

Feature	Planned start	Urgent start
Typical setting	Outpatient dialysis unit or home	Hospital ward or intensive care
What triggers it	Rising symptoms or chemistry changes anticipated over weeks	Severe potassium, acid or fluid problems, or severe AKI
Vascular access	Matured arteriovenous fistula or graft, or peritoneal catheter placed weeks earlier	Temporary catheter in a large neck or groin vein
Pace of first sessions	Gradual, sometimes shorter early sessions	Dictated by the emergency
Choice of modality	Discussed in advance; hemodialysis, peritoneal dialysis or pre-emptive transplant	Usually hemodialysis or CRRT; other options revisited later
Main risks	Access complications, blood pressure dips	Catheter infection and clotting, circulatory instability

The pattern the table reveals is why preparation is the single most important thing a person with advancing kidney disease can do. An urgent start with a temporary catheter is sometimes unavoidable, particularly in AKI. In chronic disease it usually reflects a missed opportunity: the decline was faster than expected, or referral came late, or a fistula was not ready.

A planned start does not mean starting early. It means having everything ready so that when the clinical signs appear, treatment can begin the following week in a calm room rather than that night in an emergency department. Those two experiences, with identical lab values, feel like different diseases.

Continuous or intermittent: how the hospital setting shapes the start

In intensive care, when to start is bound up with how to start. A critically ill person with sepsis, low blood pressure and severe AKI often cannot tolerate a standard four-hour hemodialysis session, because pulling fluid off quickly may drop pressure further and starve organs of blood. CRRT solves this by running slowly over the whole day, removing fluid and waste at a rate the circulation can absorb.

This changes the calculus of timing in subtle ways. Because CRRT is gentler, teams can afford to wait for a clear indication without worrying that a later start will force a brutal session. It also allows fine control of fluid balance in people receiving large volumes of intravenous drugs and nutrition, which is one of the commonest reasons it is chosen. The Mayo Clinic notes that dialysis can be delivered in hospital during acute illness and that the form used depends on the patient’s condition.

Intermittent hemodialysis remains the standard once a person is stable enough to tolerate it, and many patients move from one to the other during a single admission. Neither form has been shown to improve survival over the other in the general intensive care population, so the choice rests on hemodynamics, logistics and the individual case.

What the setting does not change is the principle established by STARRT-AKI. Whether continuous or intermittent, the therapy waits for a reason. In the trial, the accelerated group received predominantly CRRT in many centers, and still gained nothing over patients who waited for a defined indication. A gentler machine does not make an unnecessary treatment necessary.

For families at an intensive care bedside, the practical translation is simple: a decision not to start dialysis today is usually a sign of a team watching carefully, not a team giving up.

Why preparation for dialysis begins months before the first session

The most useful conversation about timing often happens long before the timing question arrives. The reason is anatomy. Hemodialysis needs a way to move blood out of the body and back at a high rate, and the safest route is an arteriovenous fistula: a surgical connection between an artery and a vein in the forearm or upper arm that makes the vein enlarge and toughen. The Mayo Clinic notes that a fistula needs several weeks to months to mature before it can be used. Create it too late and the person starts with a temporary catheter, which carries a higher risk of infection and clotting.

Peritoneal dialysis needs its own lead time. A soft catheter is placed in the abdomen and given time to heal in, and the person or a family member learns the exchange technique, which the NHS notes is usually taught over a period of training before independent use at home.

Transplant preparation is longer still: assessment, matching, and if a living donor is available, coordinating two operations.

This is why kidney units aim to hold an education session when eGFR falls into the range where failure within a year or two is plausible, well before symptoms. The NIH kidney institute encourages people to learn about all options, including conservative management, while there is time to choose rather than react.

There is an emotional dimension too. Being told a fistula is being made can feel like being told dialysis is imminent. It is not. It is closer to buying insurance. Many people carry a mature fistula for a year or more before it is used, and some never need it. Preparation buys the freedom to wait safely, which, as the trials show, is precisely what good timing requires.

What the first days and weeks after starting usually look like

Once the decision is made, the first stretch is an adjustment period rather than a sudden transformation. For center-based hemodialysis, the NHS describes a typical pattern of three sessions a week lasting about four hours each. Early sessions are sometimes shortened while the team assesses how the person’s blood pressure and chemistry respond, and settings are adjusted week by week.

Common early experiences include tiredness after sessions, occasional cramps or lightheadedness as fluid is removed, and a period of learning what the new routine demands of the diet, especially limits on potassium, phosphorus, salt and fluid. Many people notice that appetite and sleep improve over the first weeks as waste levels fall; some feel the difference within days, others take longer. Individual responses vary widely and no timeline is a promise.

Peritoneal dialysis begins with a training phase, then daily exchanges at home or overnight with a machine. The main early tasks are technique and vigilance for signs of infection at the catheter site or in the fluid.

For people starting after AKI in hospital, the picture is different again. Kidney function is checked frequently, and sessions may be paused to see whether urine output and blood tests are recovering on their own. Recovery from AKI can unfold over days to weeks, and the NHS notes that many people regain kidney function when the underlying cause is treated, so the early phase is as much about deciding when to stop as when to continue.

Across all settings, the first month is when medicines are reviewed, because some drugs are removed by dialysis and others accumulate when the kidneys fail. Any change to a prescription in this period should come from the prescribing team, and any new symptom is worth reporting rather than enduring.

What people often get wrong about starting dialysis

The first misconception is the threshold myth: that dialysis begins the moment eGFR hits 15 or 10. As the IDEAL trial showed, a symptom-guided later start carried no survival penalty, and most people in the trial’s late group started for clinical reasons rather than because they reached the target number. The value opens a window; it is not a switch.

The second is the opposite error: that waiting is always safer. It is not. Once fluid overload, dangerous potassium or uremic symptoms appear, delay carries real risk, and an urgent start with a temporary catheter is harder on the body than a planned one. The evidence supports waiting under supervision for a clinical reason, not waiting past it.

The third is that starting early protects the remaining kidney function. STARRT-AKI found the reverse signal in acute illness: more people who started early remained dependent on dialysis at 90 days than those who waited.

The fourth is that a fistula operation means dialysis is imminent. It usually means the team is preparing, so that a later start can be calm rather than rushed.

The fifth is that dialysis is the only choice once kidneys fail. Transplant assessment, sometimes before dialysis, and conservative kidney management are both real pathways described by the NIH kidney institute.

The sixth is that once dialysis begins it cannot stop. In AKI, stopping is common when the kidneys recover. In chronic disease, a transplant ends the need for it, and some people choose, with their team, to withdraw from it.

Each of these misunderstandings tends to push people toward fear or toward false reassurance. The evidence supports neither. It supports readiness, attention and a decision made in the room with the people who know the case.

Conservative kidney management: when not starting is the plan

For some people, the right answer to when to start renal replacement therapy is never, by choice. Conservative kidney management, sometimes called supportive care, is an active treatment plan that manages the effects of kidney failure with medicines, diet, and symptom control, without dialysis or transplant. The NIH kidney institute describes it as a legitimate option that people may choose after discussion with their care team.

It is most often considered by people who are very frail, who have several other serious illnesses, or who judge that the burdens of dialysis would outweigh its benefits for the life they want to lead. Dialysis for someone in advanced age with limited mobility can mean three hospital trips a week and recovery time after each; for some, the added time it offers is spent largely on treatment. Others weigh the same facts and choose dialysis. Both decisions are reasonable, and neither should be made under pressure.

Conservative management is not the absence of care. It includes controlling fluid with diuretics, managing potassium and acid levels with diet and medicines, treating anemia, relieving itch, nausea and breathlessness, and planning ahead for what the person wants as the illness advances. Kidney teams usually work alongside palliative care specialists, whose expertise is in comfort and quality of life, not only at the end of it.

People who choose this path are followed just as closely as those preparing for dialysis. Some change their minds as circumstances shift, and the option to start remains open unless the person decides otherwise. The most important thing a family can understand is that this is a decision about how to live with a serious illness, made with full information, and that choosing it is not giving up.

Questions to ask your care team

Timing conversations go better when the person knows what to ask. The questions below are ones nephrologists say they wish more patients raised, and none of them has a wrong answer.

• Looking at my trend over the last year, how fast is my kidney function falling, and what does that suggest about the next twelve months?
• Which specific problems would make you recommend starting: fluid, potassium, acid, symptoms, or something else? What are we watching for in my case?
• What are we doing now to delay the need, and how will we know if those measures stop working?
• Am I a candidate for a transplant, and if so, could it happen before dialysis? Is there anyone in my life who might be assessed as a living donor?
• If I need dialysis, which form fits my life best, and what would I need to prepare at home or at work?
• When should access surgery happen, and how long will a fistula or catheter need before it can be used?
• Which of my current medicines will change when kidney function drops further or when dialysis starts, and who will make those changes?
• What would conservative kidney management look like for me, and who would be involved?
• What symptoms should prompt me to call the unit between appointments, and who do I call out of hours?
• If I start dialysis and later want to stop, or my kidneys recover, how would that decision be made?

Writing the answers down, or bringing someone to listen, helps. Kidney disease unfolds over years, and the person who asks these questions early tends to arrive at the decision point informed rather than frightened. The team’s role is to give honest answers and to keep the decision where it belongs: with the person, guided by the clinicians who know their case.

When to call your doctor

Because the trigger for starting renal replacement therapy is usually a change in how a person feels or in what their blood shows, knowing when to report a change is part of good timing. This is not a self-diagnosis list. It is a guide to what should prompt a call to the kidney team, or emergency care, so that measurements can be taken quickly.

Seek emergency care without delay for breathlessness at rest or when lying flat, chest pain, a heartbeat that feels very irregular or slow, severe muscle weakness that comes on over hours, confusion or drowsiness that is new, seizures, or vomiting that prevents any fluid staying down. These can signal fluid in the lungs, dangerous potassium levels or severe uremia, all of which the NHS and Mayo Clinic identify as complications of kidney failure that need urgent treatment.

Contact the kidney unit promptly, within the same day, for rapidly increasing swelling of the legs or face, a marked fall in urine output, persistent nausea or loss of appetite over several days, new itching or a metallic taste that is affecting eating, or unexplained weight change over a week. For people with a fistula, graft or catheter, redness, warmth, pain or discharge at the site, or a fistula that no longer buzzes under the fingertips, warrants a same-day call.

People with known kidney disease who develop a vomiting or diarrheal illness, a high fever, or who are unable to drink normally should also make contact early, because dehydration can tip stable kidneys into acute injury, as the NHS notes in its guidance on AKI.

None of these signs means dialysis will start. Each means the team should look. Prompt reporting is what turns an urgent start into a planned one, and it is the single most practical way a person shares in timing their own care.

Frequently asked questions

When do you need renal replacement therapy?

Renal replacement therapy is usually needed when the kidneys can no longer keep blood chemistry and fluid balance safe despite other treatments. Nephrologists look for waste buildup causing symptoms such as poor appetite, nausea and confusion; fluid overload that resists diuretics; potassium or acid levels that cannot be controlled; and a steep or accelerating decline. Kidney failure is defined by an eGFR below 15, but the actual start is timed to the person, not the number.

At what eGFR do you start dialysis?

There is no fixed eGFR at which dialysis must start. An eGFR under 15 defines kidney failure, yet many people are monitored safely below that for months. The IDEAL trial compared planned starts at eGFR 10 to 14 with starts at 5 to 7 and found no survival difference. Most late-group patients began earlier than planned because of symptoms, which confirms that clinical signs, not a threshold, usually decide the timing.

What are the signs it's time to start dialysis?

Clinicians weigh several problems rather than one sign: uremic symptoms such as loss of appetite, nausea, sleep disturbance and difficulty concentrating; fluid overload causing breathlessness that diuretics no longer control; high potassium that threatens heart rhythm; and acidosis that cannot be corrected. A rapidly steepening decline also matters. These are assessed by the kidney team with blood tests and examination, so new symptoms should be reported promptly rather than self-interpreted.

What are the new AKI dialysis guidelines on timing?

Current guidance for acute kidney injury advises starting renal replacement therapy urgently when life-threatening fluid, potassium or acid problems exist, and otherwise waiting for a clear indication rather than acting on a creatinine value alone. This approach is supported by the STARRT-AKI trial, which found no survival benefit from accelerated starts, more dialysis dependence at 90 days among early starters, and recovery without dialysis in 38 percent of patients who waited.

Is early vs late dialysis initiation better for survival?

Large randomized trials found no survival advantage for early initiation in either setting. In chronic kidney disease, the IDEAL trial showed equal survival with symptom-guided later starts. In critical illness, STARRT-AKI showed 90-day mortality of 43.9 percent with accelerated starts and 43.7 percent with standard starts. Early initiation exposed people to procedures they might not need, so guidelines now favor starting for a defined clinical reason with preparation already complete.

Can dialysis be stopped once it starts?

Yes, in several circumstances. After acute kidney injury, kidneys often recover as the underlying illness is treated, and dialysis is paused or stopped when urine output and blood tests improve; the NHS notes that many people regain function. In chronic kidney disease, a successful transplant removes the need for dialysis. Some people also decide, with their care team, to withdraw from dialysis and move to conservative management. Any such decision is made jointly with the treating clinicians.

Why is a fistula created before dialysis is needed?

An arteriovenous fistula, a surgical connection between an artery and a vein, needs several weeks to months to enlarge and toughen before it can be used, according to the Mayo Clinic. Creating it early means that when a clinical reason to start appears, treatment can begin in a planned way rather than through a temporary neck or groin catheter, which carries higher infection and clotting risk. Having a fistula does not mean dialysis is imminent.

What is the difference between CRRT and regular hemodialysis?

Continuous renal replacement therapy, or CRRT, filters blood slowly around the clock and is used in intensive care for people whose blood pressure is too unstable for rapid fluid removal. Standard hemodialysis runs in sessions of about four hours, typically three times a week according to the NHS. Neither has been shown to improve survival over the other in general intensive care patients; the choice depends on the person’s circulation and clinical needs.

Does waiting to start dialysis damage the kidneys further?

The evidence points the other way. In the STARRT-AKI trial, more people who started dialysis early remained dependent on it at 90 days, 10.4 percent versus 6.0 percent, suggesting that early treatment may hinder recovery in acute illness. In chronic disease, supervised waiting in the IDEAL trial carried no survival penalty. Waiting is safe when it is watchful; the risk comes from delaying once a clear indication such as fluid overload or high potassium has appeared.

What is conservative kidney management?

Conservative kidney management is a planned approach that treats the effects of kidney failure with medicines, diet and symptom control without dialysis or transplant. The NIH kidney institute describes it as a legitimate option, often considered by people who are very frail or living with several other serious illnesses. It includes controlling fluid, potassium and acid levels, treating anemia and relieving symptoms, usually with palliative care specialists alongside the kidney team, and the choice can be revisited.

References

• NHS: Dialysis
• NHS: Acute kidney injury
• NIH NIDDK: Choosing a Treatment for Kidney Failure

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.